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Introduction {#onco13178-sec-0003}
============

Historically, patients with cancer were advised to rest, recover, and save energy, avoiding engaging in tiring physical activity. Nevertheless, starting in the late 1980s [1](#onco13178-bib-0001){ref-type="ref"}, new data progressively emerged, supporting the notion that physical activity (PA; defined as any bodily movement produced by skeletal muscles that results in energy expenditure) and exercise (EX; including only those planned, structured, and repetitive activities aimed at improving or maintaining one or more components of physical fitness) may provide relevant benefits in oncology. In cancer survivors, an inverse correlation between PA and mortality or recurrence rate was reported [2](#onco13178-bib-0002){ref-type="ref"}, [3](#onco13178-bib-0003){ref-type="ref"}, [4](#onco13178-bib-0004){ref-type="ref"}. Moreover, EX can play a beneficial role during and after oncological treatments, leading to clinically meaningful improvements in physical fitness (aerobic, strength, flexibility, and body composition) [5](#onco13178-bib-0005){ref-type="ref"}, [6](#onco13178-bib-0006){ref-type="ref"}, [7](#onco13178-bib-0007){ref-type="ref"}, quality of life (QoL) [8](#onco13178-bib-0008){ref-type="ref"}, treatment‐related side effects [5](#onco13178-bib-0005){ref-type="ref"}, [9](#onco13178-bib-0009){ref-type="ref"}, and psychological outcomes (such as anxiety, depression, self‐esteem, and energy level and vitality) [5](#onco13178-bib-0005){ref-type="ref"}. Nevertheless, the American College of Sport Medicine guidelines for EX in cancer are mainly directed to patients with breast, prostate, colon, gynecologic, and hematological cancer, and no universal recommendations are available for lung cancer.

Lung malignancies are the leading cause of cancer‐related death [10](#onco13178-bib-0010){ref-type="ref"}. Non‐small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) are the main histological subtypes of lung cancer, and NSCLC accounts for around 85% of all cases. Despite meaningful recent diagnostic and therapeutic advances, the overall prognosis remains poor for affected patients. In terms of overall survival (OS) according to stage, the eighth edition of TNM classification for lung cancer showed an OS by clinical stage at 24 and 60 months ranging from 97% and 92% for patients at stage I to 10% and 0% for patients at stage IVB [11](#onco13178-bib-0011){ref-type="ref"}. Despite crucial progress obtained in terms of availability of innovative treatments (such as targeted therapy and immunotherapy), lung cancer remains associated with physical, psychological, and social difficulties, which exert a negative influence on patients' QoL. Moreover, various cancer‐ and treatment‐related complications, such as dyspnea, muscle wasting, pain, fatigue, loss of appetite, and deterioration of physical fitness and lung function, may further impair patients' status [12](#onco13178-bib-0012){ref-type="ref"}. All these outcomes have been suggested to be potentially ameliorable with EX, despite the lack of dedicated guidelines for lung cancer. Several biological mechanisms have been proposed in order to explain the link between cancer and EX. The main hypothesis and evidence include the control of chronic low‐grade inflammation and the modulation of metabolic dysregulation substances (e.g., insulin, glucose, and insulin‐like growth factors) and sex hormones. Moreover, it seems that PA and EX could have an impact on oxidative stress and immune‐related function, modifying some crucial mechanisms connected to tumor microenvironment (e.g., angiogenesis, proliferation, and apoptosis) [13](#onco13178-bib-0013){ref-type="ref"}.

In this article, we perform an in‐depth revision of available data investigating the role of PA and EX in patients with lung cancer undergoing surgical and/or medical treatments. Moreover, we analyze potential underlying biological mechanisms, peculiar to lung cancer oncogenesis, and suggest a structured, multidimensional way forward to definitively address the potential impact of PA and EX on lung cancer outcomes.

Materials and Methods {#onco13178-sec-0004}
=====================

A comprehensive Pubmed and <http://clinicaltrials.gov> search was performed on July 24, 2019, to identify the published and ongoing studies exploring the role of PA and EX in lung cancer. The following keywords were used: exercise, physical activity, lung cancer, non‐small cell lung cancer, small cell lung cancer. In order to acquire a complete and in‐depth perspective on this emerging topic, all original articles (randomized clinical trials, nonrandomized controlled trials, and observational data) investigating PA and EX in lung cancer were considered. Abstracts not published in extenso, case reports, non‐English full texts, and theses were excluded. Participants' inclusion criteria were adults affected by lung cancer, surgically treated, during or after medical therapies; animal studies were also considered. Regarding intervention, we considered physical activity (including also exercise by definition), defined as supervised or unsupervised interventions including any type of exercise applied to patients with lung cancer and performed for at least 4 weeks. All inclusion criteria were evaluated, in title, abstract, and full text of original papers, by two independent reviewers.

Investigated Outcomes in Lung Cancer {#onco13178-sec-0005}
====================================

A series of studies have investigated the impact of PA and EX on measurable outcomes such as cardiorespiratory fitness, pulmonary function, strength and muscle mass, fatigue, quality of life, psychological status, and sleep quality (Table [1](#onco13178-tbl-0001){ref-type="table"} and Fig. [1](#onco13178-fig-0001){ref-type="fig"}).

###### 

Main interventional studies after surgery and/or during medical treatments in lung cancer

+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+
| Author                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Patients and study type                   | Duration and type of intervention                                                                                                                                 | Primary outcomes                            | Secondary outcomes                                                                                                                                                              | Main results                                             |
+:=======================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================+:==========================================+:==================================================================================================================================================================+:============================================+:================================================================================================================================================================================+:=========================================================+
| Peddle‐Mclntyre et al. [54](#onco13178-bib-0054){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 14 NSCLC                                  | 12 wks of a distance‐based intervention with printed materials +12 wks follow‐up                                                                                  | Feasibility                                 | Physical activity level, QoL                                                                                                                                                    | ↓ eligibility and attrition rate                         |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | (I--IIIB)                                 |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ physical activity level                                |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Single arm                                |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ QoL (some domains)                                     |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ pain                                                   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | Short‐term benefits                                      |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+
| Sommer et al. [51](#onco13178-bib-0051){ref-type="ref"}, [52](#onco13178-bib-0052){ref-type="ref"}, [53](#onco13178-bib-0053){ref-type="ref"}, [54](#onco13178-bib-0054){ref-type="ref"}, [55](#onco13178-bib-0055){ref-type="ref"}, [56](#onco13178-bib-0056){ref-type="ref"}, [57](#onco13178-bib-0057){ref-type="ref"}, [58](#onco13178-bib-0058){ref-type="ref"}, [59](#onco13178-bib-0059){ref-type="ref"}, [60](#onco13178-bib-0060){ref-type="ref"}, [61](#onco13178-bib-0061){ref-type="ref"}, [62](#onco13178-bib-0062){ref-type="ref"}, [63](#onco13178-bib-0063){ref-type="ref"}, [64](#onco13178-bib-0064){ref-type="ref"} | 40 NSCLC                                  | 2 wks of preoperative +12 wks of postoperative aerobic and strength activity + multidisciplinary intervention                                                     | Safety, feasibility, and QoL                | Anxiety, depression, distress, perceived social support, smoking, alcohol, and physical activity habits; VO2peak; 6MWT; strength; pulmonary function; patient‐reported outcomes | ↑ QoL (some domains)                                     |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | (I--IIIA)                                 |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↓ anxiety, depression, and distress levels               |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | RCT                                       |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | Preoperative interventions not feasible                  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | Postoperative interventions safe and feasible            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ 6MWT                                                   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ strength                                               |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+
| Messaggi‐Sartor et al. [42](#onco13178-bib-0042){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 37 NSCLC                                  | 8 wks of aerobic exercise and high‐intensity respiratory muscle training vs. UC                                                                                   | VO2peak                                     | Respiratory muscle strength, QoL, IGF‐1 and IGFBP‐3 levels                                                                                                                      | ↑ QoL (some domains)                                     |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | (I--II)                                   |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ VO2peak                                                |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | RCT                                       |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ respiratory muscle strength                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ IGFBP‐3 serum level                                    |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+
| Dhillon et al. [29](#onco13178-bib-0029){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 112 NSCLC (III--IV), SCLC                 | 2 months of supervised and unsupervised physical activity program +4 months follow‐up +6 months follow‐up vs. education materials only                            | Fatigue                                     | QoL; ADL; IADL; anxiety, distress, depression; sleep quality; dyspnea; 6MWT; handgrip strength; senior fitness test; physical activity level; sedentary behavior; survival      | ↑ physical activity levels in Ex group at 4 and 6 months |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | RCT                                       |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+
| Cavalheri et al. [43](#onco13178-bib-0043){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 17 NSCLC                                  | 8 wks of individual supervised aerobic and strength program vs. control group                                                                                     | Exercise capacity (VO2peak and 6MWT)        | Physical activity level; sedentary behavior; strength; QoL; fatigue; anxiety, depression; lung function                                                                         | ↑ VO2peak                                                |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | (I--IIIA)                                 |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ 6MWT                                                   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | RCT                                       |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+
| Chen et al. [96](#onco13178-bib-0096){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 111 LC (I--IV)                            | 12 wks of home‐based walking program and weekly exercise counseling vs. usual care +3 months follow‐up                                                            | Sleep quality and rest‐activity rhythms     | NA                                                                                                                                                                              | ↑ sleep quality                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | RCT                                       |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+
| Solheim et al. [89](#onco13178-bib-0089){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 64 (26 NSCLC,                             | 6 wks of multimodal intervention (anti‐inflammatory drugs, oral supplements, nutritional counseling, and home‐based aerobic and strength exercise) vs. usual care | Feasibility, compliance                     | Weight; muscle mass; physical activity level, 6MWT, handgrip strength; nutritional status; fatigue; safety; survival                                                            | Feasible                                                 |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | III--IV)                                  |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | 60% compliance for Ex                                    |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | RCT                                       |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ weight                                                 |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+
| Zhang et al. [24](#onco13178-bib-0024){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 96 NSCLC                                  | 12 wks of Tai Chi vs. low impact exercise (control group)                                                                                                         | Fatigue                                     | NA                                                                                                                                                                              | ↓ fatigue (some domains)                                 |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | (I--IV), SCLC                             |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | RCT                                       |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+
| Chen et al. [30](#onco13178-bib-0030){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 116 LC (I--IV)                            | 12 wks of home‐based walking program and weekly exercise counseling vs. usual care +3 months follow‐up                                                            | Anxiety and depression                      | Cancer‐related symptoms                                                                                                                                                         | ↓ anxiety and depression                                 |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | RCT                                       |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+
| Quist et al. [44](#onco13178-bib-0044){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 114 NSCLC (IIIb--IV), SCLC (ED)           | 6 wks of aerobic and strength program                                                                                                                             | VO2peak                                     | Strength, 6MWT, FEV1, QoL, cancer‐related symptoms, anxiety, depression                                                                                                         | ↑ VO2peak                                                |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Single arm                                |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ 6MWT                                                   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ strength                                               |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ emotional well‐being                                   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↓ anxiety                                                |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+
| Sahli et al. [80](#onco13178-bib-0080){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 70 NSCLC                                  | 12 wks of WBV vs. CRT vs. usual care                                                                                                                              | 6MWT                                        | Change in exercise capacity, strength, and QoL after radical treatment; maximal exercise capacity; strength; QoL after training                                                 | ↑ 6MWT                                                   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | (I--IV), SCLC (LD), mesothelioma (I--III) |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ quadriceps force in CRT after training program         |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | RCT                                       |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+
| Sahli et al. [86](#onco13178-bib-0086){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 45 NSCLC                                  | 12 wks of strength program (whole‐body vibration or conventional resistance training) vs. usual care                                                              | Changes in muscle mass and strength         | NA                                                                                                                                                                              | ↓ muscle mass and strength after radical treatment       |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | (I--III), SCLC                            |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | Complete recovery after rehabilitation                   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | RCT                                       |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↓ muscle mass and strength in control groups over time   |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+
| Edvardsen et al. [52](#onco13178-bib-0052){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 61 NSCLC                                  | 20 wks of high‐intensity aerobic and strength program vs. UC                                                                                                      | VO2peak                                     | Pulmonary function; muscle mass; strength; daily physical functioning; QoL                                                                                                      | ↑ VO2peak                                                |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | (I--IV)                                   |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ DLCO                                                   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | RCT                                       |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ strength                                               |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ muscle mass                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ daily physical functioning                             |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ QoL                                                    |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+
| Kuehr et al. [31](#onco13178-bib-0031){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 40 NSCLC (IIA--IV)                        | 8 wks of aerobic and strength (in patients and home‐based periods) + 8 wks follow‐up                                                                              | Feasibility                                 | 6MWT; strength; QoL; fatigue; psychological impairment                                                                                                                          | Feasible                                                 |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Single arm                                |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ 6MWT                                                   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ strength                                               |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↓ QoL                                                    |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+
| Chang et al. [70](#onco13178-bib-0070){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 65 LC                                     | 12 wks and of walking vs. usual care +3 months follow‐up                                                                                                          | 6MWT; pulmonary function; QoL               | NA                                                                                                                                                                              | ↑ FEV1 at 3 and 6 months                                 |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Quasi‐experimental (2 arms)               |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ 6MWT at 1, 3, and 6 months                             |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+
| Arbane et al. [47](#onco13178-bib-0047){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 53 NSCLC                                  | 5 days of strength and mobility inpatient program +12 wks of aerobic and strength program vs. usual care                                                          | QoL                                         | 6MWT; strength; length of stay and postoperative complication                                                                                                                   | ↓ loss of strength in Ex group                           |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | RCT                                       |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+
| Arbane et al. [55](#onco13178-bib-0055){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 131 NSCLC (I--IV)                         | 4 wks of aerobic and strength (5 days inpatients) and walking program vs. usual care                                                                              | Physical activity level                     | Ex tolerance; strength; QoL; length to stay, postoperative complication                                                                                                         | ↑ QoL in patients with airflow obstruction               |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | RCT                                       |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+
| Hoffman et al. [25](#onco13178-bib-0025){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 5 NSCLC (IIA--IIIA)                       | 16 wks of walking and balance (with Nintendo Wii)                                                                                                                 | Fatigue                                     | Cancer‐related symptoms; 6MWT; QoL                                                                                                                                              | ↑ 6MWT                                                   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Single arm                                |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ QoL                                                    |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↓ cancer‐related symptoms                                |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↓ fatigue                                                |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+
| Hoffman et al. [26](#onco13178-bib-0026){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 7 NSCLC                                   | 6 wks of walking and balance (with Nintendo Wii)                                                                                                                  | Feasibility                                 | Fatigue; self‐efficacy; functional performance (steps/day)                                                                                                                      | Feasible                                                 |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | (I--IIIA)                                 |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↓ fatigue                                                |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Single arm                                |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ walking steps/day                                      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ self‐efficacy                                          |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+
| Stigt et al. [50](#onco13178-bib-0050){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 57 NSCLC                                  | 12 wks of aerobic and strength program +3 months follow‐up +6 months follow‐up vs. usual care                                                                     | QoL                                         | 6MWT; pain; feasibility in patients undergoing chemotherapy                                                                                                                     | ↑ 6MWT after 3 months of intervention                    |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | RCT                                       |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ pain                                                   |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+
| Henke et al. [53](#onco13178-bib-0053){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 46 NSCLC (IIIA--IV), SCLC                 | 3 cycles of chemotherapy of aerobic, strength (every other day), and endurance plus breathing techniques (5 days per week) vs. usual care                         | Activity of daily living (ADL‐Bartel Index) | QoL; 6MWT; strength; dyspnea                                                                                                                                                    | ↑ ADL                                                    |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | RCT                                       |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ 6MWT                                                   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ strength                                               |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↓ dyspnea                                                |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ QoL (some domains)                                     |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+
| Cheville et al. [32](#onco13178-bib-0032){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 66 (34 LC, IV)                            | 8 wks of walking and strength home‐based program vs. usual care                                                                                                   | Mobility and activity                       | QoL; fatigue; pain; sleep quality; ability to perform daily activities                                                                                                          | ↑ mobility                                               |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | RCT                                       |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ sleep quality                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↓ fatigue                                                |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+
| Andersen et al. [65](#onco13178-bib-0065){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 59 NSCLC                                  | 9 wks (3wk supervised +3wk unsupervised +3wk supervised) of aerobic interval training and walking                                                                 | Adherence                                   | FEV1; VO2max; QoL                                                                                                                                                               | 44% completed the program                                |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | (I--IV), SCLC                             |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | 69% continued to be active after rehabilitation          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Pragmatic uncontrolled trial              |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+
| Granger et al. [45](#onco13178-bib-0045){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 15 (10 LC                                 | 8 wks of aerobic and strength program (inpatient and outpatient home‐based) vs. usual care                                                                        | Safety and feasibility                      | 6MWT; functional mobility; QoL                                                                                                                                                  | Safe and feasible                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | I--IV)                                    |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ functional mobility                                    |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | RCT                                       |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ 6MWT                                                   |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+
| Hwang et al. [46](#onco13178-bib-0046){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 24 NSCLC (IIIA--IV)                       | 8 wks of high‐intensity interval training vs. usual care                                                                                                          | VO2peak                                     | Strength; oxygenation during exercise; insulin resistance; inflammatory response; QoL                                                                                           | ↑ VO2peak                                                |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | RCT                                       |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ circulation                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ respiratory and muscular function                      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ peak exercise                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↓ dyspnea                                                |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↓ fatigue                                                |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+
| Quist et al. [66](#onco13178-bib-0066){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 29 NSCLC (III--IV), SCLC (ED)             | 6 wks of aerobic, strength, relaxation supervised sessions, walking, and relaxation home‐based sessions                                                           | Safety and feasibility                      | VO2peak; strength; 6MWT; FEV1; QoL                                                                                                                                              | Safe and feasible                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Single arm                                |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ VO2peak                                                |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ 6MWT                                                   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ strength                                               |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ emotional well‐being                                   |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+
| Temel et al. [48](#onco13178-bib-0048){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 25 NSCLC (IIIB--IV)                       | 12 wks of aerobic and strength program                                                                                                                            | Feasibility                                 | QoL; symptom severity; mood; 6MWT; strength; survival                                                                                                                           | 44% completed the program                                |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Single arm                                |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ elbow extension strength                               |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↓ cancer‐related symptoms                                |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+
| Jones et al. [27](#onco13178-bib-0027){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 20 NSCLC (IA--IIIB)                       | 14 wks of aerobic training                                                                                                                                        | VO2peak                                     | QoL; fatigue                                                                                                                                                                    | ↑ peak workload                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Single arm                                |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ functional well‐being                                  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↓ fatigue                                                |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+
| Spruit et al. [67](#onco13178-bib-0067){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 10 NSCLC and SCLC                         | 8 wks of aerobic and strength program                                                                                                                             | 6MWT and peak cycling load                  | Pulmonary function; dyspnea                                                                                                                                                     | ↑ 6MWT                                                   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Single arm                                |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ peak cycling load                                      |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+
| Tarumi et al. [71](#onco13178-bib-0071){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 82 NSCLC (stage IIB--IV)                  | 8 wks of relaxation, respiratory training, cough training, lower‐extremity exercise, and training of daily living                                                 | Pulmonary function                          | NA                                                                                                                                                                              | ↑ FVC                                                    |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Single arm (retrospective)                |                                                                                                                                                                   |                                             |                                                                                                                                                                                 | ↑ FEV1                                                   |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+
| Brocki et al. [49](#onco13178-bib-0049){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 78 LC                                     | 10 wks of aerobic and strength exercise vs. usual care +12 months follow‐up                                                                                       | QoL                                         | 6MWT; lung function                                                                                                                                                             | ↓ body pain (at 10 weeks)                                |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                           |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | RCT                                       |                                                                                                                                                                   |                                             |                                                                                                                                                                                 |                                                          |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+
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Abbreviations: ADL, activities of daily living; 6MWT, 6‐minute walking test; CRT, conventional resistance training; DLCO, diffusion capacity of the lung for carbon monoxide; ED, extensive disease; Ex, exercise; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; IADL, instrumental activities of daily living; IGF‐1, insulin‐like growth factor 1; IGFBP‐3, insulin‐like growth factor binding protein 3; LC, lung cancer; LD, limited disease; NA, not available; NSCLC, non‐small cell lung cancer; QoL, quality of life; RCT, randomized controlled trial; SCLC, small cell lung cancer; UC, usual care; VO2max, maximal oxygen consumption; VO2peak, peak rate of oxygen consumption; WBV, whole‐body vibration.
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Fatigue {#onco13178-sec-0006}
-------

Cancer‐related fatigue is defined as "a distressing, persistent, subjective sense of physical, emotional, and/or cognitive tiredness or exhaustion related to cancer and/or cancer treatment that is not proportional to recent activity and interferes with usual functioning" [14](#onco13178-bib-0014){ref-type="ref"}. In lung cancer, about 90% [15](#onco13178-bib-0015){ref-type="ref"} of patients undergoing chemotherapy and 57% [16](#onco13178-bib-0016){ref-type="ref"} of surgically resected patients experience this side effect. Different genetic and behavioral risk factors can predispose patients to cancer‐related fatigue [17](#onco13178-bib-0017){ref-type="ref"}, which has numerous manifestations, such as weakness, sleep disturbance, and lower concentration or attention, that cause a negative impact on work, mood, and social relationships, decreasing QoL [17](#onco13178-bib-0017){ref-type="ref"}. Several candidate factors have been suggested as underlying mechanisms inducing cancer‐related fatigue. Among them, an increase in proinflammatory cytokines (such as c‐reactive protein, IL‐6, and TNF‐α) and angiogenic modulators (mainly vascular endothelial growth factor \[VEGF\]), anemia, disturbance in the hypothalamic‐pituitary adrenal axis, altered brain serotonin metabolism, and defect in adenosine triphosphate regeneration seem to play a crucial role [18](#onco13178-bib-0018){ref-type="ref"}, [19](#onco13178-bib-0019){ref-type="ref"}.

By modulating these biological mechanisms, EX may improve the management of cancer‐related fatigue by reducing symptoms' severity. Indeed, EX has been demonstrated to assist fatigue management in patients with cancer and cancer survivors affected by different types of malignancies (such as breast, colon, prostate, etc.) [8](#onco13178-bib-0008){ref-type="ref"}. Moreover, a recent meta‐analysis has found that EX and psychological intervention are more effective than a pharmacological approach to counteract such distress [20](#onco13178-bib-0020){ref-type="ref"}. Observational studies in lung cancer reported an inverse correlation between PA and symptoms of fatigue [21](#onco13178-bib-0021){ref-type="ref"}, [22](#onco13178-bib-0022){ref-type="ref"}, [23](#onco13178-bib-0023){ref-type="ref"}. In particular, D\'Silva et al. objectively assessed PA and sedentary time in 127 patients with NSCLC (stage I--IV) and found that moderate‐ to vigorous‐intensity activity was associated with fewer fatigue symptoms, whereas sedentary time was associated with increased fatigue, negatively affecting QoL and physical and functional well‐being [21](#onco13178-bib-0021){ref-type="ref"}. Moreover, Janssen et al. described a routine rehabilitation program, offered to patients with lung cancer, composed of aerobic and strength exercises with a frequency of three times per week. Fifty patients (stage I--IIIA) started the program with a completion rate of 86%. After 12 weeks, fatigue, QoL, and cardiorespiratory fitness were significantly improved from the baseline assessment [22](#onco13178-bib-0022){ref-type="ref"}. Similarly, other interventional studies showed that EX ameliorates fatigue‐related symptoms [24](#onco13178-bib-0024){ref-type="ref"}, [25](#onco13178-bib-0025){ref-type="ref"}, [26](#onco13178-bib-0026){ref-type="ref"}, [27](#onco13178-bib-0027){ref-type="ref"}, especially if initiated early after surgery [28](#onco13178-bib-0028){ref-type="ref"}. For instance, a randomized controlled trial including 96 patients with lung cancer (including NSCLC stage I--IV and SCLC) undergoing chemotherapy compared the effect of a tai chi program (performed every other day) versus low impact exercise (as a control group) on cancer‐related fatigue. The tai chi group reported an improvement in total fatigue score compared with the control group at 6 weeks (59.6 ± 11.3 vs. 66.8 ± 11.9, *p* \< .05) and 12 weeks (53.3 ± 11.8 vs. 59.3 ± 12.2, *p* \< .05) [24](#onco13178-bib-0024){ref-type="ref"}. Although these findings seem to support the benefit of EX for cancer‐related fatigue in lung cancer, other interventional studies reported no changes in fatigue levels after a targeted exercise program [29](#onco13178-bib-0029){ref-type="ref"}, [30](#onco13178-bib-0030){ref-type="ref"}, [31](#onco13178-bib-0031){ref-type="ref"}, [32](#onco13178-bib-0032){ref-type="ref"}. In this regard, a trial randomized 112 patients with lung cancer (NSCLC stage III--IV and SCLC) to 8‐week supervised and unsupervised PA sessions plus a behavioral support program, and general health education materials or control (general health education material only). After the intervention, at 4 and 6 months, no significant changes were detected in terms of fatigue, QoL, symptom severity, physical or functional status, and survival between the two groups [29](#onco13178-bib-0029){ref-type="ref"}. Nevertheless, the engagement in an EX program was never associated with an exacerbation in fatigue levels. Further studies are required to consolidate the real contribution of exercise on cancer‐related fatigue in lung cancer.

Quality of Life {#onco13178-sec-0007}
---------------

QoL is defined by a subjective and multidimensional concept that includes physical, psychological, and social domains and has shown a prognostic impact in lung cancer [33](#onco13178-bib-0033){ref-type="ref"}, [34](#onco13178-bib-0034){ref-type="ref"}. The World Health Organization describes QoL as "an individual\'s perception of their position in life, in the context of the culture and value systems in which they live and relation to their goals, expectations, standard and concerns" [35](#onco13178-bib-0035){ref-type="ref"}. Patients with lung cancer have a long‐lasting QoL impairment compared with healthy people, especially regarding physical health score, after both surgery and chemotherapy or radiotherapy [36](#onco13178-bib-0036){ref-type="ref"}, [37](#onco13178-bib-0037){ref-type="ref"}, [38](#onco13178-bib-0038){ref-type="ref"}. Nevertheless, the level of QoL reduction might also depend on disease stage, prognosis, and tumor localization [39](#onco13178-bib-0039){ref-type="ref"}. A longitudinal study among 107 patients with lung cancer (stage I--IV) showed a direct correlation between QoL level and time dedicated in walking activities over a 6‐month follow‐up period, with a QoL increase by 0.03 points per additional minute of walking time per week [40](#onco13178-bib-0040){ref-type="ref"}. A comprehensive systematic review including 16 randomized controlled trials with different cancer types (breast, colorectal, lymphoma, prostate, and lung) concluded that EX significantly improved QoL (mean difference, 5.55; 95% confidence interval \[CI\], 3.16--7.90; *p* \< .001), during and after medical treatment. Moreover, during treatment, a gain in both psychological and physical variables was observed, whereas after completion of therapies an improvement in only the physical aspects was evident [41](#onco13178-bib-0041){ref-type="ref"}.

Focusing on studies including only patients with lung cancer, no clear advantage in terms of QoL after applying a physical exercise program is evident [29](#onco13178-bib-0029){ref-type="ref"}, [31](#onco13178-bib-0031){ref-type="ref"}, [32](#onco13178-bib-0032){ref-type="ref"}, [42](#onco13178-bib-0042){ref-type="ref"}, [43](#onco13178-bib-0043){ref-type="ref"}, [44](#onco13178-bib-0044){ref-type="ref"}, [45](#onco13178-bib-0045){ref-type="ref"}, [46](#onco13178-bib-0046){ref-type="ref"}, [47](#onco13178-bib-0047){ref-type="ref"}, [48](#onco13178-bib-0048){ref-type="ref"}, [49](#onco13178-bib-0049){ref-type="ref"}. A randomized controlled trial attempted to assess the impact of EX intervention on QoL in 81 patients undergoing thoracotomy. Although the study closed prematurely (after 57 patients randomized) because of the introduction of video‐assisted thoracoscopic surgery, after 12 weeks of intervention and during follow‐up, a very high drop‐out rate was reported (8/23 patients in the active group and 11/25 in the control group performed the functional test), with no changes in QoL and increased pain in the active group [50](#onco13178-bib-0050){ref-type="ref"}. On the other hand, there are studies reporting a QoL improvement after training [25](#onco13178-bib-0025){ref-type="ref"}, [51](#onco13178-bib-0051){ref-type="ref"}, [52](#onco13178-bib-0052){ref-type="ref"}, [53](#onco13178-bib-0053){ref-type="ref"}, [54](#onco13178-bib-0054){ref-type="ref"}, [55](#onco13178-bib-0055){ref-type="ref"}. Among them, a study with 40 patients with stage I--IIIA NSCLC showed a significant improvement in global quality of life (*p* = .0032), emotional well‐being (*p* \< .0001), mental health component (*p* = .0004), and a reduction in anxiety, depression, and distress after 12 weeks of multidisciplinary intervention including PA (aerobic, strength, and nature activity), dietary guidance, social counseling, and other options (e.g., counseling for smoking cessation) [51](#onco13178-bib-0051){ref-type="ref"}. Considering the controversial association between exercise and QoL in lung cancer care, further studies with a solid design and an adequate sample size are required to clarify this issue.

Pulmonary Function {#onco13178-sec-0008}
------------------

The assessment of respiratory functionality by a global spirometry test is a crucial step to define therapeutic perspectives in lung cancer. In particular, the predicted postoperative of forced expiratory volume in 1 second (FEV1) and the diffusion capacity of carbon monoxide (DLCO) are the most utilized parameters to evaluate the surgical risk [56](#onco13178-bib-0056){ref-type="ref"} and are associated with the prognosis of patients with lung cancer [57](#onco13178-bib-0057){ref-type="ref"}, [58](#onco13178-bib-0058){ref-type="ref"}. Surgical resection, chemotherapy, radiotherapy, and comorbidities (such as chronic obstructive pulmonary disease \[COPD\]) may be harmful for the pulmonary system, reducing respiratory functionality [59](#onco13178-bib-0059){ref-type="ref"}, [60](#onco13178-bib-0060){ref-type="ref"}, [61](#onco13178-bib-0061){ref-type="ref"}. Historically, the respiratory system is defined as *overbuilt* for exercise, and therefore training does not appear to confer a significant adaptation in lung of healthy human subjects [62](#onco13178-bib-0062){ref-type="ref"}. Nevertheless, the role of EX is still controversial in pulmonary diseases. EX in patients with COPD is largely studied, and a recent meta‐analysis including 21 randomized controlled trials has analyzed the role of whole‐body exercise on pulmonary function in adult participants with chronic lung diseases (mainly COPD). The results demonstrated a small but significant improvement in spirometry values in the EX group as compared with controls, suggesting that in certain conditions the respiratory system may adapt in response to training [63](#onco13178-bib-0063){ref-type="ref"}.

In lung cancer, the effect of EX on pulmonary parameters was investigated with preliminary supportive evidence [43](#onco13178-bib-0043){ref-type="ref"}, [64](#onco13178-bib-0064){ref-type="ref"}, [65](#onco13178-bib-0065){ref-type="ref"}, [66](#onco13178-bib-0066){ref-type="ref"}, [67](#onco13178-bib-0067){ref-type="ref"}. An individual supervised training (three times per week, 60 minutes per session) was proposed in 17 patients with stage I--IIIA NSCLC. After 8 weeks of training, an increase was observed in exercise capacity (the primary outcome), without any significant improvement in other parameters, such as strength, QoL, fatigue, anxiety, depression, and pulmonary function [43](#onco13178-bib-0043){ref-type="ref"}. However, in the first year after surgery, patients usually experience an increase in pulmonary parameters [68](#onco13178-bib-0068){ref-type="ref"} that may be attributed to compensatory mechanisms, such as the expansion of the remaining lobes and vascular tissues [69](#onco13178-bib-0069){ref-type="ref"}. In this postoperative context, studies testing different training programs are consistent in detecting an improvement in respiratory muscle strength and/or functionality [42](#onco13178-bib-0042){ref-type="ref"}, [52](#onco13178-bib-0052){ref-type="ref"}, [70](#onco13178-bib-0070){ref-type="ref"}. A retrospective study evaluated the outcome of a comprehensive rehabilitation schedule on pulmonary function in 82 patients with lung cancer (stage IIB--IV). The program included relaxation (at least once per day), respiratory training (at least once day before surgery), cough training (at least once per day before surgery), activities of daily living (after surgery) and lower‐extremity exercise (high‐intensity aerobic exercise, 5 days per week for 45 minutes). At 8--10 weeks, significant increases in forced vital capacity (FVC; +6.4%, *p* = .0096) and in FEV1 (+ 10.4%, *p* \< .0001) were found, whereas the DLCO decreased. Even in current or former smokers, an improvement in FEV1 was observed, whereas patients with respiratory impairment experienced a greater increase in both FVC (+13.9%, *p* = .0025) and FEV1 (+ 22.5%, *p* \< .0001) [71](#onco13178-bib-0071){ref-type="ref"}. Collectively, these results should be interpreted cautiously, because some studies lack a control group and several aspects need to be further defined, mainly about the potential role of EX on postsurgery compensatory mechanisms.

Cardiorespiratory Fitness {#onco13178-sec-0009}
-------------------------

Peak oxygen consumption (VO~2peak~) and the 6‐minute walking test (6MWT) are the most applied assessments for cardiorespiratory fitness in lung cancer. Cardiorespiratory fitness reflects the capability to introduce, transport, and use oxygen, and it is an important index of functionality, health, and longevity. Similar to pulmonary function, VO~2peak~ can provide clinically relevant diagnostic and prognostic information. It is inversely related to perioperative and postoperative complications, and it is an independent predictor of survival [72](#onco13178-bib-0072){ref-type="ref"}. To date, three studies have investigated the relationship between cardiorespiratory fitness and survival in lung cancer [73](#onco13178-bib-0073){ref-type="ref"}, [74](#onco13178-bib-0074){ref-type="ref"}, [75](#onco13178-bib-0075){ref-type="ref"}. In this regard, Jones et al. prospectively found that each 50 meters of improvement in 6MWT was associated with a reduction of 13% in risk of death in patients with metastatic NSCLC. Furthermore, compared with patients in the lowest 6MWT group, the overall reduction of death risk improved together with the increase in functional capacity (from 39% to 52%) [75](#onco13178-bib-0075){ref-type="ref"}. Cardiorespiratory fitness was compromised in patients with lung cancer versus healthy participants (mean difference, 0.87 mL × kg^−1^ × min^−1^; 95% CI, −12.1 to −5.3; *p* \< .001) [76](#onco13178-bib-0076){ref-type="ref"}, and this impairment did not improve after therapies. Fifty patients with NSCLC (stage I--IIIB) were monitored for 6 months, from diagnosis (pretreatment) to the following 10 weeks (during treatment) and 6 months (usually after completion of therapies). 6MWT declined significantly from diagnosis to during treatment (−42.7 m; 95% CI, −71.4 to 14.0; *p* \< .01) and continued to be lower after 6 months (−77.9 m; 95% CI, −144.3 to 11.4; *p* = .02) [77](#onco13178-bib-0077){ref-type="ref"}.

Cardiorespiratory fitness involves several consecutive steps, including respiratory and cardiovascular systems, vasculature, blood, and skeletal muscle. In healthy persons the most important factor that limits exercise capacity is the cardiac muscle [62](#onco13178-bib-0062){ref-type="ref"}, but in lung malignancies many cancer‐related factors concur to diminishing the cardiorespiratory fitness [78](#onco13178-bib-0078){ref-type="ref"}. First, the presence of a tumor mass, together with related surgical procedures, may affect the respiratory system by reducing diffusion capacity. Second, in case of advanced disease, the oxidative capacity of skeletal muscles is impaired with a reduction in capillarization and mitochondrial density. Moreover, chemotherapeutic agents and radiotherapy may harm cardiac pump, blood cell populations, and vascular function [78](#onco13178-bib-0078){ref-type="ref"}.

Although in lung diseases the respiratory system could play a major role in limiting exercise capacity, in long‐term postpneumonectomy patients (mean 5.5 years after surgery), it was suggested that it was mainly limited by the cardiovascular system [79](#onco13178-bib-0079){ref-type="ref"}. Nevertheless, physical exercise may mitigate these impairments and improve the cardiorespiratory fitness in lung cancer. A randomized controlled trial investigated the effects of high‐intensity endurance and strength training on cardiorespiratory fitness as primary outcome. Sixty‐one patients with NSCLC (stage I--IV) were enrolled in an exercise program (60 minutes for three times per week). After 20 weeks, with an adherence rate of 88%, the authors found an increase of 4.5 ± 3.4 mL × kg^−1^ × min^−1^ in the EX group, whereas the control group reported a decrease of --0.6 ± 2.7 mL × kg^−1^ × min^−1^ in cardiorespiratory fitness [52](#onco13178-bib-0052){ref-type="ref"}. Similarly, a recent study including patients with surgically resected NSCLC (stage I--II) detected a significant VO~2peak~ increment in the EX group versus control [42](#onco13178-bib-0042){ref-type="ref"}. Globally considered, although some studies did not report any significant change in functional capacity following a training period [27](#onco13178-bib-0027){ref-type="ref"}, [29](#onco13178-bib-0029){ref-type="ref"}, [45](#onco13178-bib-0045){ref-type="ref"}, [47](#onco13178-bib-0047){ref-type="ref"}, [48](#onco13178-bib-0048){ref-type="ref"}, [49](#onco13178-bib-0049){ref-type="ref"}, [55](#onco13178-bib-0055){ref-type="ref"}, [64](#onco13178-bib-0064){ref-type="ref"}, [65](#onco13178-bib-0065){ref-type="ref"}, the majority agreed on the potential beneficial effect of exercise on cardiorespiratory fitness [22](#onco13178-bib-0022){ref-type="ref"}, [25](#onco13178-bib-0025){ref-type="ref"}, [31](#onco13178-bib-0031){ref-type="ref"}, [42](#onco13178-bib-0042){ref-type="ref"}, [43](#onco13178-bib-0043){ref-type="ref"}, [44](#onco13178-bib-0044){ref-type="ref"}, [46](#onco13178-bib-0046){ref-type="ref"}, [50](#onco13178-bib-0050){ref-type="ref"}, [52](#onco13178-bib-0052){ref-type="ref"}, [53](#onco13178-bib-0053){ref-type="ref"}, [66](#onco13178-bib-0066){ref-type="ref"}, [67](#onco13178-bib-0067){ref-type="ref"}, [70](#onco13178-bib-0070){ref-type="ref"}, [80](#onco13178-bib-0080){ref-type="ref"}.

Strength and Muscle Mass {#onco13178-sec-0010}
------------------------

Strength and muscle composition (muscle mass or size) are the most accurate parameters to evaluate muscle function. Patients with lung cancer may suffer from muscle dysfunction for disease‐related metabolic disorders, oncological treatments, physical inactivity, and malnutrition [81](#onco13178-bib-0081){ref-type="ref"}. Muscle mass alterations occurring during cancer define pathological conditions, such as cachexia (a multifactorial syndrome characterized by severe muscle wasting, malnutrition, and systemic inflammation) and sarcopenia (decreased muscle mass). The majority of patients affected by advanced lung cancer experience cachexia (69%) or sarcopenia (47%) [82](#onco13178-bib-0082){ref-type="ref"}, both related to a poor prognosis [12](#onco13178-bib-0012){ref-type="ref"}, [81](#onco13178-bib-0081){ref-type="ref"}, [83](#onco13178-bib-0083){ref-type="ref"}. Considering that strength is closely linked to muscle mass, patients with lung cancer may also have relevant impairments of this parameter. Indeed, patients with NSCLC (stage I--IIIA) had a significantly lower handgrip strength as compared with healthy controls, with a mean difference of −6 kg (*p* = .023) [76](#onco13178-bib-0076){ref-type="ref"}. Muscular strength is an important parameter, and, in healthy persons, it represents a predictor of all‐cause mortality [84](#onco13178-bib-0084){ref-type="ref"}. A study investigating the impact of strength on survival found that handgrip strength is an independent prognostic factor in patients with NSCLC and gastrointestinal cancer with advanced and metastatic disease [85](#onco13178-bib-0085){ref-type="ref"}.

EX, especially resistance training, is a potent modulator of skeletal muscle and could counteract muscle dysfunction in patients with lung cancer. The majority of interventional studies that included strength assessment in their secondary outcomes found a positive effect of EX [31](#onco13178-bib-0031){ref-type="ref"}, [44](#onco13178-bib-0044){ref-type="ref"}, [47](#onco13178-bib-0047){ref-type="ref"}, [48](#onco13178-bib-0048){ref-type="ref"}, [52](#onco13178-bib-0052){ref-type="ref"}, [53](#onco13178-bib-0053){ref-type="ref"}, [64](#onco13178-bib-0064){ref-type="ref"}, [66](#onco13178-bib-0066){ref-type="ref"}, [80](#onco13178-bib-0080){ref-type="ref"}, whereas few of them reported no relevant effect [43](#onco13178-bib-0043){ref-type="ref"}, [46](#onco13178-bib-0046){ref-type="ref"}, [55](#onco13178-bib-0055){ref-type="ref"}. However, relatively few studies explored the role of EX on muscle mass in lung cancer. Salhi et al. investigated the impact of a rehabilitation program on muscle mass and strength in 45 patients with lung cancer (stage I--III) who underwent radical oncological treatments (surgery and/or radiotherapy and/or chemotherapy). The rehabilitation consisted of an initial warming‐up (20 minutes), followed by resistance training of upper and lower limb muscles with conventional resistance training or whole‐body vibration training, 3 days per week for 12 weeks after treatment completion. A significant decrease in muscle cross‐sectional area and in quadriceps force with a conservation in fat‐free mass, measured with bioelectrical impedance, was observed after treatments. Following a 12‐week rehabilitation program, full recovery in muscle strength and mass was detected in the intervention arm, whereas the control group experienced a further decline from baseline [86](#onco13178-bib-0086){ref-type="ref"}.

As suggested in the context of preclinical studies, aerobic and strength training seem to induce a relevant benefit against cancer cachexia [87](#onco13178-bib-0087){ref-type="ref"}, [88](#onco13178-bib-0088){ref-type="ref"}. To our knowledge, only one study is available in patients with cachexia. The MENAC trial tests a multimodal intervention to attenuate and/or prevent cancer cachexia, which included anti‐inflammatory drugs, oral nutritional supplements, nutritional counseling, and an exercise program, on patients with lung and pancreatic cancer. To assess intervention safety and feasibility, a phase II cohort randomized 46 patients (26 with advanced NSCLC). The home‐based EX intervention consisted of aerobic training (30 minutes two times per week) and six individualized strength tasks (three times per week). Six weeks later, the intervention was shown to be safe and feasible, with a compliance of 76% for anti‐inflammatory drugs, 60% for exercise, and 48% for nutritional supplements. No significant changes in PA, muscle mass and strength, fatigue, and nutritional status were reported, probably because of the small sample size [89](#onco13178-bib-0089){ref-type="ref"}. The phase III cohort of MENAC trial, which will include 240 patients, is currently enrolling patients (NCT02330926) to clarify the efficacy of this multimodal intervention.

Psychological Status and Sleep Quality {#onco13178-sec-0011}
--------------------------------------

Patients with lung cancer may experience several health problems, including psychological distress, because of cancer or undesired effects of its treatment. PA and EX may contribute to limiting these impairments.

The beneficial role of PA and EX in anxiety and depression is well established [90](#onco13178-bib-0090){ref-type="ref"}, [91](#onco13178-bib-0091){ref-type="ref"} through the modulation of monoamine and cortisol levels, leading to adaptation in limbic structures [92](#onco13178-bib-0092){ref-type="ref"}. The prevalence of anxiety, depression, and sleep disorders among patients with lung cancer is 33%, 34%, and 45%--57%, respectively [93](#onco13178-bib-0093){ref-type="ref"}, [94](#onco13178-bib-0094){ref-type="ref"}. In the context of lung cancer, few studies have considered the potential role of EX to improve these symptoms, finding positive [44](#onco13178-bib-0044){ref-type="ref"}, [51](#onco13178-bib-0051){ref-type="ref"} or neutral effects [31](#onco13178-bib-0031){ref-type="ref"}. Chen et al. investigated the impact of EX on anxiety and depression symptoms as a primary outcome in a sample of patients with lung cancer (stage I--IV). Enrolled participants (*n* = 116) were randomly assigned to a 12‐week moderate‐intensity walking program, three times per week for 40 minutes, or usual care. After the intervention, anxiety (*p* = .009) and depression (*p* = .00006) levels were significantly diminished, and the effect was maintained over time (anxiety, *p* = .006; depression, *p* = .004) [30](#onco13178-bib-0030){ref-type="ref"}.

EX can improve sleep quality in the general population [95](#onco13178-bib-0095){ref-type="ref"}, but also in cancer survivors [96](#onco13178-bib-0096){ref-type="ref"}. Sleep disturbances are a common problem in oncology care and affect a large portion of patients with lung cancer, especially during the chemotherapy period [94](#onco13178-bib-0094){ref-type="ref"}. EX seems to contribute to improving sleep quality in patients with lung cancer [23](#onco13178-bib-0023){ref-type="ref"}, [32](#onco13178-bib-0032){ref-type="ref"}, [96](#onco13178-bib-0096){ref-type="ref"}, although results of different studies are controversial [29](#onco13178-bib-0029){ref-type="ref"}, [30](#onco13178-bib-0030){ref-type="ref"}. A home‐based walking program proposed by Chen et al. has shown that 12 weeks of moderate‐intensity EX is effective over time in improving both subjective (*p* = .001) and objective (*p* = .023) sleep quality in a sample of patients with lung cancer (stage I--IV) compared with the control group [96](#onco13178-bib-0096){ref-type="ref"}.

Biological Mechanisms {#onco13178-sec-0012}
=====================

The molecular mechanisms by which PA and EX could influence lung cancer outcomes remain elusive. Data from literature suggest that PA and EX may counteract some specific cancer cells' acquired capabilities (hallmarks of cancer) and, at the same time, prevent chemotherapy‐related adverse events (Fig. [1](#onco13178-fig-0001){ref-type="fig"}).

The ability to promote an aberrant angiogenesis represents a main hallmark of cancer. In fact, as an adaptive response to hypoxia, cancer cells activate the hypoxia‐inducible factor 1‐alpha (HIF‐1α) pathway to promote angiogenesis through proangiogenetic factors, mainly VEGF‐α [97](#onco13178-bib-0097){ref-type="ref"}. Under normal conditions, EX stimulates a physiological angiogenetic process and VEGF release in skeletal muscles in a HIF‐1--independent manner [98](#onco13178-bib-0098){ref-type="ref"}. Nevertheless, how EX modulates angiogenesis in an oncological setting is not clear. Treadmill exercise for a period of 4 weeks, five times per week and 60 minutes each session, has demonstrated to significantly increase VEGF serum levels in mice inoculated with Lewis lung cancer (LLC) cells, as compared with baseline (*p* = .015), but without significant differences in terms of survival rate or tumor growth compared with the control group [99](#onco13178-bib-0099){ref-type="ref"}. Alves et al. observed 2.5‐fold higher mRNA levels of VEGF‐α (*p* \< .05) in an LLC mice model undergoing daily high‐intensity interval training after tumor cell injection compared with sedentary mice, with a significant reduction of tumor mass (−52% after 18 days) and benefit in survival [100](#onco13178-bib-0100){ref-type="ref"}.

The capability to escape cell death and apoptosis is another hallmark of cancer, and p53 plays a crucial role as a tumor suppressor protein [97](#onco13178-bib-0097){ref-type="ref"}. EX may affect oncogenesis through activation of p53‐induced apoptosis. In this regard, daily wheel running for 4 weeks appeared to reduce primary tumor growth (but not distant metastases), as compared with a control group (*p* \< .01), with a significant increase in p53 intratumoral levels (*p* \< .01), in a murine model of lung adenocarcinoma. Similarly, levels of Bax and caspase 3 (two proapoptotic proteins in the p53 pathway) were significantly increased. Interestingly, this cancer model was p53 wild type, suggesting the potential role of EX in stabilizing p53 and avoiding its downregulation [101](#onco13178-bib-0101){ref-type="ref"}.

The phosphoinositide 3‐kinase--AKT pathway (through mTOR and S6 kinase) and the RAS‐MAP kinase cascade (through ERK1 and ERK2) are involved in enhancing cell proliferation and survival, as well as in lung cancer cells resistance to chemotherapy and radiation [102](#onco13178-bib-0102){ref-type="ref"}, [103](#onco13178-bib-0103){ref-type="ref"}. The effect of EX has been studied in lung adenocarcinoma A549 cells incubated with human serum, collected pre‐ or post‐EX, or foetal bovine serum as control. A significant reduction of proliferation and survival for cells treated with post‐EX serum compared with control (*p* \< .05 and *p* \< .001, respectively) was observed. A relevant reduction of cell survival was also evident when comparing cells treated with pre‐ and post‐EX serum (*p* \< .001). To explore the potential underlying reasons, the authors measured activated (phosphorylated) AKT levels through immunoblotting, revealing a significant reduction between cells incubated with pre‐ and post‐EX serum (*p* \< .001). Similar findings were observed for mTOR, S6 kinase, and ERK1 and ERK2 activation [104](#onco13178-bib-0104){ref-type="ref"}.

Another possible mechanism underlying the antitumorigenic impact of EX is related to immunomodulation, particularly by increasing proinflammatory cytokine levels and natural killer (NK) cell infiltration in the tumor microenvironment. Pedersen et al. found that EX (wheel running) in LLC mice significantly reduced tumor volume (−58%), with an upregulation of proinflammatory cytokines (IL‐1a and inducible nitric oxide synthase \[iNOS\]) and markers for NK and T‐cell activity [105](#onco13178-bib-0105){ref-type="ref"}. In a prospective randomized study in postsurgical patients with NSCLC, 16 weeks of tai chi chuan training was demonstrated to significantly promote proliferation of peripheral blood mononuclear cells, as compared with both basal levels (*p* \< .001) and a control group (*p* \< .05), with an increase in their cytotoxicity demonstrated by incubation with lung adenocarcinoma A549 cells (*p* \< .001). Moreover, a relevant increase in circulating NK cell percentage, natural killer T, and dendritic CD11c cells between the exercise and control groups was detected [106](#onco13178-bib-0106){ref-type="ref"}. In another prospective randomized trial, the control group, including 16 patients with surgically resected NSCLC, experienced a decrease in ratio of IFN‐γ--producing CD3+ T lymphocytes (T1) to IL‐4--producing CD3+ T lymphocytes (T2) and an increase in cortisol levels during recovery time. Conversely, the experimental arm (16 postsurgical patients with NSCLC) who followed a guided 16‐week moderate‐intensity tai chi program (60 minutes per session, three sessions per week) managed to preserve a stable T1‐to‐T2 ratio and cortisol levels [107](#onco13178-bib-0107){ref-type="ref"}. Interestingly, preliminary evidence suggests that chemotherapy‐treated patients with lung cancer who joined exercise sessions using resistance bands managed to maintain white blood cell levels during treatment compared with a control group [108](#onco13178-bib-0108){ref-type="ref"}.

Considerations About Exercise Prescription in Patients with Lung Cancer {#onco13178-sec-0013}
=======================================================================

Mounting evidence suggests that EX is safe in patients with lung cancer, both after surgery and during and after medical treatments. Different programs with a variety of activities were explored, such as tai chi, aerobic and strength exercise, walking, balance, and breathing techniques. The most often applied frequency was two or three times per week, and time per session ranged from 5 to 120 minutes. Across the studies, all the levels of training intensity (light, moderate, and vigorous), when reported, appeared to be well tolerated by patients. However, most patients with lung cancer are insufficiently active or sedentary, and a series of studies reported a low adherence and high drop‐out rate from EX programs [43](#onco13178-bib-0043){ref-type="ref"}, [48](#onco13178-bib-0048){ref-type="ref"}, [65](#onco13178-bib-0065){ref-type="ref"}, [109](#onco13178-bib-0109){ref-type="ref"}, [110](#onco13178-bib-0110){ref-type="ref"}. Among drop‐out reasons, cancer‐related side effects and, mostly, lack of interest and motivation represent key contributors.

There are many barriers limiting the adherence to a PA program. Some of them are also common in healthy people, such as lack of access to services or lack of interest, but others are specifically related to health status, disease course, and therapeutic approach. In addition, environmental and personal exercise preferences, fun, and social implications are important factors that influence the participation and consistency over time to a physical activity program [111](#onco13178-bib-0111){ref-type="ref"}. In patients with lung cancer (and their caregivers) there is a higher risk of experiencing exacerbations of psychosocial distress because of the widely shared stigmatization of this disease based on the close link between lung cancer and smoking [112](#onco13178-bib-0112){ref-type="ref"}.

Several models, applicable also in cancer populations, are applied to trigger motivation to perform exercise (such as social cognitive theory, theory of planned behavior, and self‐determination theory). Knowledge and integration of these theories in clinical practice may help patients to adopt and maintain EX or PA as part of their lifestyle [113](#onco13178-bib-0113){ref-type="ref"}. The American Cancer Society and American College of Sport Medicine recommend avoiding inactivity and suggest that patients with cancer should engage in regular PA. In detail, at least 150 minutes per week of moderate aerobic activity, or 75 minutes of vigorous aerobic activity, with flexibility and strength exercise two or three times per week should be performed [5](#onco13178-bib-0005){ref-type="ref"}, [114](#onco13178-bib-0114){ref-type="ref"}. This goal could be difficult to achieve, especially for physically deconditioned patients. For this reason, the EX program should be flexible (particularly during treatment periods), start easily, and progress slowly according to patient\'s rhythm and body response. Moreover, an interpatient heterogeneity in physical, psychological status, and treatment‐related side effects needs to be considered. According to available evidence, an accurate baseline assessment, including clinical, physical, and psychosocial conditions, is fundamental to schedule a tailored EX program. Recognizing the presence of relevant comorbidities to adapt activity and avoid potential EX‐induced risks is fundamental. The presence of extreme fatigue or high physical limitation could be a contraindication to start an EX program, or a low cardiorespiratory fitness may suggest performing EX with low intensity and for short time [5](#onco13178-bib-0005){ref-type="ref"}.

Considering all these factors, in clinical practice close collaboration among oncologists and kinesiologists (or cancer exercise specialists or physiotherapists) may allow developing specific EX programs based on patient\'s needs, preferences, and physical and psychological status. The final aims are to improve patient\'s physical fitness and quality of life, reduce treatment‐related side effects, and increase the motivation to adopt and maintain an active lifestyle over time (Fig. [2](#onco13178-fig-0002){ref-type="fig"}). Several trials are ongoing to enrich the currently available amount of evidence‐based data (Table [2](#onco13178-tbl-0002){ref-type="table"}).

![Tailored exercise program: a proposed model.](ONCO-25-e555-g002){#onco13178-fig-0002}

###### 

Randomized controlled trials currently ongoing or recently concluded (without available results) in lung cancer

+-------------------------------------------------------+-------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------+-----------------------------------------------------------+
| PI and Sponsor                                        | Number      | Title                                                                                                                                                                                                                                                              | Estimated participants          | Primary outcome                                           |
+:======================================================+:============+:===================================================================================================================================================================================================================================================================+:================================+:==========================================================+
| Chia‐Chin Lin                                         | NCT03482323 | Improving Survival in Lung Cancer Patients: A Randomized Controlled Trial of Aerobic Exercise and Tai‐Chi Interventions                                                                                                                                            | 372 NSCLC                       | 1‐year OS                                                 |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
| The University of Hong Kong                           |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
+-------------------------------------------------------+-------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------+-----------------------------------------------------------+
| Tora S. Solheim                                       | NCT02330926 | A Randomized, Open‐Label Trial of a Multimodal Intervention (Exercise, Nutrition and Anti‐Inflammatory Medication) Plus Standard Care Versus Standard Care Alone to Prevent/Attenuate Cachexia in Advanced Cancer Patients Undergoing Chemotherapy \[MENAC trial\] | 240 LC and PDAC                 | Body weight                                               |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
| Norwegian University of Science and Technology        |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
+-------------------------------------------------------+-------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------+-----------------------------------------------------------+
| Kathleen Lyons                                        | NCT03500393 | A Remotely Supervised Exercise Program for Lung Cancer Patients Undergoing Chemo‐Radiation (REM)                                                                                                                                                                   | 50 LC                           | Recruitment and retention                                 |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
| Dartmouth‐Hitchcock Medical Center                    |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
+-------------------------------------------------------+-------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------+-----------------------------------------------------------+
| Lee W. Jones                                          | NCT01068210 | Lung Cancer Exercise Training Study: A Randomized Trial of Aerobic Training, Resistance Training, or Both in Lung Cancer Patients                                                                                                                                  | 160 LC                          | VO2peak                                                   |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
| Memorial Sloan Kettering Cancer Center                |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
+-------------------------------------------------------+-------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------+-----------------------------------------------------------+
| Sandy Jack                                            | NCT03334071 | Exercise Regimens Before and During Advanced Cancer therapy: A Pilot Study to Investigate Improvements in Physical Fitness with Exercise Training Programme Before and During Chemotherapy in Advanced Lung Cancer Patients                                        | 100 NSCLC                       | Adherence to exercise training program and adverse events |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
| University Hospitals Southampton NHS Foundation Trust |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
+-------------------------------------------------------+-------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------+-----------------------------------------------------------+
| Morten Quist                                          | NCT03066271 | PRIME ‐ Pre Radiotherapy Daily Exercise Training in Non‐Small Cell Lung Cancer                                                                                                                                                                                     | 40 NSCLC                        | VO2peak                                                   |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
| Rigshospitalet, Denmark                               |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
+-------------------------------------------------------+-------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------+-----------------------------------------------------------+
| Paul LaStayo                                          | NCT03306992 | A Phase III Randomized Study Comparing the Effects of a Personalized Exercise Program (PEP) Against No Intervention in Patients with Stage I--IIIa Primary Non‐Small Cell Lung Cancer or Secondary Lung Cancer Undergoing Surgical Resection                       | 200 LC (primary or secondary)   | 6MWT                                                      |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
| University of Utah                                    |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
+-------------------------------------------------------+-------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------+-----------------------------------------------------------+
| Amy Hoffman                                           | NCT03724331 | Understanding the Post‐Surgical Non‐Small Cell Lung Cancer Patient\'s Symptom Experience                                                                                                                                                                           | 279 NSCLC                       | Fatigue                                                   |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
| University of Nebraska                                |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
+-------------------------------------------------------+-------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------+-----------------------------------------------------------+
| Brett Bade                                            | NCT03352245 | Assessing the Feasibility of a Patient‐centered Activity Regimen in Patients with Advanced Stage Lung Cancer                                                                                                                                                       | 40 NSCLC                        | Steps count and adherence to recommendations              |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
| Yale University                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
+-------------------------------------------------------+-------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------+-----------------------------------------------------------+
| Marta Kramer Mikkelsen                                | NCT03411200 | Engaging the Older Cancer Patient; Patient Activation Through Counseling, Exercise and Mobilization ‐ Pancreatic, Biliary Tract, and Lung Cancer (PACE‐Mobil‐PBL) ‐ A Randomized Controlled Trial                                                                  | 100 NSCLC, PDAC, biliary cancer | Lower body strength                                       |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
| Herlev and Gentofte Hospital                          |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
+-------------------------------------------------------+-------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------+-----------------------------------------------------------+
| Jesper Holst Pedersen                                 | NCT02439073 | Postoperative Rehabilitation in Operation for LUng CAncer (PROLUCA) ‐ A Randomized Clinical Trial with Blinded Effect Evaluation                                                                                                                                   | 235 LC                          | VO2peak                                                   |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
| Rigshospitalet, Denmark                               |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
+-------------------------------------------------------+-------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------+-----------------------------------------------------------+
| Elisabeth Edvardsen                                   | NCT01748981 | Cardiorespiratory Fitness and Effect of Training After Lung Cancer Surgery. A Randomized Controlled Trial                                                                                                                                                          | 80 NSCLC                        | VO2peak                                                   |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
| Oslo University Hospital                              |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
+-------------------------------------------------------+-------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------+-----------------------------------------------------------+
| Grandes Gonzalo                                       | NCT01786122 | Physical Exercise to Improve the Quality of Life in Cancer Patients During Treatment Process: EFFICANCER Study                                                                                                                                                     | 250 NSCLC, GI, and BC           | QoL                                                       |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
| Basque Health Service                                 |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
+-------------------------------------------------------+-------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------+-----------------------------------------------------------+
| Liu Jui Fang                                          | NCT02757092 | The Impacts of Pulmonary Rehabilitation Therapy on Patients After Thoracic Surgery                                                                                                                                                                                 | 120 mixed                       | Pulmonary complication                                    |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
| Chang Gung Memorial Hospital                          |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
+-------------------------------------------------------+-------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------+-----------------------------------------------------------+
| Sara Tenconi                                          | NCT02405273 | Effects of Early Pulmonary Rehabilitation and Long‐Term Exercise on Functioning, Quality of Life and Postoperative Outcome in Lung Cancer Patients                                                                                                                 | 140 NSCLC                       | 6MWT                                                      |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
| Arcispedale Santa Maria Nuova‐IRCCS                   |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
+-------------------------------------------------------+-------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------+-----------------------------------------------------------+
| Miklos Pless                                          | NCT02585362 | Influence of a Specially Formulated Whey Protein Supplement in Combination with Physical Exercise and Nutrition Program on Physical Performance in Cancer Outpatients                                                                                              | 88 mixed                        | Physical performance                                      |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
| Kantonsspital Winterthur KSW                          |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
+-------------------------------------------------------+-------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------+-----------------------------------------------------------+
| Ling Xu                                               | NCT03244605 | Clinical Study on the Effect of Comprehensive Rehabilitation Program on Quality of Life and Long‐Term Survival in Postoperative Non‐Small Cell Lung Cancer Patients                                                                                                | 236 NSCLC                       | QoL                                                       |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
| Shanghai University of Traditional Chinese Medicine   |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
+-------------------------------------------------------+-------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------+-----------------------------------------------------------+
| Alice Ryan                                            | NCT02991677 | Exercise Effect on Chemotherapy‐Induced Neuropathic Pain, Peripheral Nerve Fibers                                                                                                                                                                                  | 60 mixed                        | Pain                                                      |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
| University of Maryland                                |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
+-------------------------------------------------------+-------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------+-----------------------------------------------------------+
| Young Sik Park                                        | NCT02121379 | Randomized Clinical Trial of 8 Weeks Pulmonary Rehabilitation in Advanced Stage Lung Cancer Patients with COPD During Cytotoxic Chemotherapy                                                                                                                       | 40 LC                           | VO2peak                                                   |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
| Seoul National University Hospital                    |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
+-------------------------------------------------------+-------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------+-----------------------------------------------------------+
| Joseph A. Greer                                       | NCT03089125 | Brief Behavioral Intervention for Dyspnea in Patients with Advanced Lung Cancer                                                                                                                                                                                    | 200 LC                          | Dyspnea                                                   |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
| Massachusetts General Hospital                        |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
+-------------------------------------------------------+-------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------+-----------------------------------------------------------+
| Oscar Gerardo Arrieta Rodríguez                       | NCT02978521 | Effect of a Pulmonary Rehabilitation Program on Skeletal Muscle Mass, Pulmonary Function, Inflammatory Response and Overall Survival on Patients Diagnosed with Non‐Small‐Cell Advanced Cancer                                                                     | 94 NSCLC                        | Pulmonary function                                        |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
| Instituto Nacional de Cancerologia de Mexico          |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
+-------------------------------------------------------+-------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------+-----------------------------------------------------------+
| Ling Xu                                               | NCT03372694 | Efficacy Study of Comprehensive Rehabilitation Program Plus Chemotherapy in Postoperative NSCLC Patients                                                                                                                                                           | 354 NSCLC                       | QoL                                                       |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
|                                                       |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
| Shanghai University of Traditional Chinese Medicine   |             |                                                                                                                                                                                                                                                                    |                                 |                                                           |
+-------------------------------------------------------+-------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------+-----------------------------------------------------------+
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Abbreviations: 6MWT, 6‐minute walking test; BC, breast cancer; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; LC, lung cancer; NSCLC, non‐small cell lung cancer; OS, overall survival; PDAC, pancreatic adenocarcinoma; PI, primary investigator; QoL, quality of life; VO2peak, peak rate of oxygen consumption.

Conclusion {#onco13178-sec-0014}
==========

As highlighted above, many questions are still open regarding optimal exercise prescription and actual impact of EX and PA on survival rate, treatment‐related side effects, and quality of life of patients with lung cancer. Although available evidence provides a strong rationale to continue pursuing and investigating these aspects from both a clinical and translational point of view, current results remain not decisive because of methodological limitations of the performed trials, small numbers of patients included (mainly affected by early‐stage lung cancer), and a general lack of tailored EX programs, taking into account individual patients' conditions, comorbidities, and preferences.

A common topic emerging from available experiences explores the potential synergistic impact of strongly integrated interdisciplinary approaches, encompassing coordinated EX and PA, nutritional, and psychological and behavioral interventions. From a theoretical standpoint, it is reasonable to speculate that behavioral and psychological intervention or counseling may reinforce motivation and compliance, thus potentially favoring adherence to tailored EX programs. On the other hand, nutritional counseling may help to counteract sarcopenia and muscle wasting, thereby rendering EX more effective in maintaining muscle mass and improving strength. Indeed, a meta‐analysis showed that combined EX and psychological intervention is more effective than a pharmacological approach to counteract fatigue [8](#onco13178-bib-0008){ref-type="ref"}. Similarly, an integrated approach encompassing EX, dietary guidance, social counseling, and a smoking cessation program [51](#onco13178-bib-0051){ref-type="ref"} clearly improved QoL, emotional well‐being, and mental health, while reducing anxiety, depression, and distress. Overall, the impact of PA and EX on QoL endpoints appears to be potentially more profound when administered as part of a multidimensional, comprehensive approach to physical, nutritional, and psychological well‐being.

In this regard, a further step to improve the awaited benefit deriving from PA and EX may be achieved by embedding a personalized physical exercise program within a multidimensional teamwork intervention for oncological patients. In this light, we are currently offering a patient‐centered approach provided by an integrated team, including dietitians, kinesiologists, and psychologists coordinated by a medical oncologist (the Focus On Research and CarE team \[FORCE\]). On one hand, these nonpharmacological interventions may help improve QoL, physical functions, psychological aspects, and treatment‐related adverse events and reduce symptoms and complications occurring during cancer care. On the other, we hypothesize that such a comprehensive approach may influence patients' immune status, thereby ultimately affecting treatment outcome (in particular for patients undergoing immunotherapy). Based on a rigorous scientific method, we aim to (A) derive tissue‐ and blood‐based immunological signature(s) predicting the outcome of immunological therapy, (B) demonstrate that EX (in context with nutritional counseling and behavioral interventions provided in an integrated fashion by the FORCE team) favorably modifies such predictive signatures, and (C) test (in a formal clinical trial) the hypothesis that specific EX preconditioning schemes (again in the context of a multidisciplinary intervention) improve the outcome(s) of patients with lung cancer undergoing immunotherapy.
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